|
Elsukova O.S., Nikitina E.A., Chuprova A.V., Kaysina O.A.
Possibilities of using a fixed combination of alogliptin and pioglitazone in patients with type 2 diabetes mellitus in everyday clinical practice
|
№2 / 2024
|
|
Demidova I.Yu., Boeva V.V.
Screening, diagnosis and treatment of early carbohydrate metabolism disorders
|
№2 / 2024
|
|
Leonova M.V.
Metformin prevents the development of atrial fibrillation
|
№2 / 2024
|
|
I.B. Zhurtova, A.M. Gubachikova, L.S. Aramisova, H.A. Abdul Moati, L.A. Anaeva
Metabolic effects of metformin in patients with type 2 diabetes mellitus and new coronavirus infection
|
№12 / 2023
|
|
A.U.k. Kazimova, Sh.M.k. Polukhova
Pharmacotherapeutic aspects of gestational diabetes mellitus against the background of impaired maternal immunity
|
№4-5 / 2023
|
|
S.V. Podachina, E.V. Biryukova, I.V. Solovievа
Combination therapy for type 2 diabetes maintains its position. Clinical case
|
№3 / 2023
|
|
N.A. Petunina, N.S. Martirosyan, F.V. Valeeva
Cardiovascular outcomes during treatment with dipeptidyl peptidase-4 inhibitors depending on renal function and combination with metformin: a systematic review
|
№11-12 / 2022
|
|
A.E. Bagriy, O.A. Prikolota, A.V. Prikolota, E.S. Mikhailichenko, I.A. Golodnikov, O.N. Bagriy, K.A. Kotova
Clinical effects of dapagliflozin in patients with type 2 diabetes mellitus and paroxysmal atrial fibrillation
|
№11-12 / 2022
|
|
L.Yu. Morgunov
Type 3 diabetes mellitus: is there a chance to become famous?
|
№4 / 2022
|
|
P.B. Shorokhova, V.L. Baranov
Differentiated approach to metformin therapy in newly diagnosed type 2 diabetes mellitus from the perspective of pharmacogenetics
|
№12 / 2021
|
|
A.F. Verbovoy, Yu.A. Dolgikh
Insulin resistance – a common enemy for endocrinologists and cardiologists
|
№12 / 2021
|
|
A.S. Ametov (1), E.A. Tertychnaya (2)
Early pathogenetic combined therapy of sugar diabetes type 2: focus on insulin resistance
|
№14 / 2019
|
Русский
